Viking Therapeutics, Inc. (NASDAQ:VKTX) today announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the ...
近年来，医疗保健领域最热门的增长领域之一是减肥药物市场，这一类药物在临床研究和实际应用中都被证明既有效又安全。你可能熟悉一些畅销药物，例如礼来的Zepbound或诺和诺德的Wegovy ...
BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of $125.00. Justin Zelin has given his Buy rating due to a ...
Now let's talk about the new kid in town. Viking focuses on GIP/GLP-1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials. As an injectable (like the Novo Nordisk and ...
周二，Viking Therapeutics（纳斯达克股票代码：VKTX）股价为32.65美元，继续受到关注。H.C. Wainwright分析师Joseph Pantginis重申了"买入"评级，目标价为102.00美元。根据InvestingPro数据，分析师对该股保持 ...
In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback